Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2375]
News [3440]
Articles [281]
Editorials [30]
Conferences [171]
elearning [101]
Regorafenib versus lomustine for relapsed glioblastoma
Dr Giuseppe Lombardi - Istituto Oncologico Veneto, Padova, Italy
Regorafenib versus lomustine for relapsed glioblastoma ( Dr Giuseppe Lombardi - Istituto Oncologico Veneto, Padova, Italy )
9 Sep 2017
Reviewing LORELEI, mindACT and ExteNET trials in breast cancer
Prof Miguel Martin - Hospital General Universitario Gregorio Marañón, Madrid...
Reviewing LORELEI, mindACT and ExteNET trials in breast cancer ( Prof Miguel Martin - Hospital General Universitario Gregorio Marañón, Madrid, Spain )
9 Sep 2017
Questioning the role of CT-scan in NSCLC post-surgery follow-up
Prof Virginie Westeel - University of Franche-Comté, Besançon, France
Questioning the role of CT-scan in NSCLC post-surgery follow-up ( Prof Virginie Westeel - University of Franche-Comté, Besançon, France )
9 Sep 2017
Osimertinib suitable for first line EGFRm lung cancer
Dr Suresh Ramalingam - Winship Cancer Institute, Atlanta, USA
Osimertinib suitable for first line EGFRm lung cancer ( Dr Suresh Ramalingam - Winship Cancer Institute, Atlanta, USA )
9 Sep 2017
FLAURA study of osimertinib versus TKI for 1st line NSCLC
Dr Suresh Ramalingam - Winship Cancer Institute, Druid Hills, USA
FLAURA study of osimertinib versus TKI for 1st line NSCLC ( Dr Suresh Ramalingam - Winship Cancer Institute, Druid Hills, USA )
9 Sep 2017
Follow-up on the IFCT-0302 trial
Prof Virginie Westeel - University of Franche-Comté, Besançon, France
Follow-up on the IFCT-0302 trial ( Prof Virginie Westeel - University of Franche-Comté, Besançon, France )
9 Sep 2017
PACIFIC trial of durvalumab for lung cancer
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
PACIFIC trial of durvalumab for lung cancer ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )
9 Sep 2017
ESMO 2017: CDK4/6 inhibitors from a patient’s perspective
Prof Kimberly Blackwell, Prof Hope Rugo, Prof Peter Schmid, Dr Mark Verrill
ESMO 2017: CDK4/6 inhibitors from a patient’s perspective ( Prof Kimberly Blackwell, Prof Hope Rugo, Prof Peter Schmid, Dr Mark Verrill )
8 Sep 2017
Editor's Choice for August 2017
Prof Gordon McVie - Founding Editor, ecancer
Editor's Choice for August 2017 ( Prof Gordon McVie - Founding Editor, ecancer )
23 Aug 2017
Introduction to iManageCancer apps - Italian translation
Introduction to iManageCancer apps - Italian translation ( )
4 Aug 2017
Introduction to iManageCancer apps - German translation
Introduction to iManageCancer apps - German translation ( )
4 Aug 2017
Editor's Choice for July 17
Prof Gordon McVie - Founding Editor, ecancer
Editor's Choice for July 17 ( Prof Gordon McVie - Founding Editor, ecancer )
28 Jul 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation